[HTML][HTML] Onset of action of indacaterol in patients with COPD: comparison with salbutamol and salmeterol-fluticasone
B Balint, H Watz, C Amos, R Owen… - … Journal of Chronic …, 2010 - ncbi.nlm.nih.gov
Background: Indacaterol is a novel, inhaled once-daily ultra-long-acting β 2-agonist for the
treatment of chronic obstructive pulmonary disease (COPD). Objectives: This study …
treatment of chronic obstructive pulmonary disease (COPD). Objectives: This study …
Onset of action of indacaterol in patients with COPD: comparison with salbutamol and salmeterol-fluticasone.
B Balint, H Watz, C Amos, R Owen… - … Journal of Chronic …, 2010 - europepmc.org
Background indacaterol is a novel, inhaled once-daily ultra-long-acting β (2)-agonist for the
treatment of chronic obstructive pulmonary disease (COPD). Objectives this study compared …
treatment of chronic obstructive pulmonary disease (COPD). Objectives this study compared …
[PDF][PDF] Onset of action of indacaterol in patients with COPD: Comparison with salbutamol and salmeterol-fluticasone
B Balint, C Amos, B Kramer - International Journal of Chronic Obstructive …, 2010 - Citeseer
Background: Indacaterol is a novel, inhaled once-daily ultra-long-acting β2-agonist for the
treatment of chronic obstructive pulmonary disease (COPD). Objectives: This study …
treatment of chronic obstructive pulmonary disease (COPD). Objectives: This study …
[PDF][PDF] Onset of action of indacaterol in patients with COPD: Comparison with salbutamol and salmeterol-fluticasone
B Balint, C Amos, B Kramer - International Journal of Chronic …, 2010 - scholar.archive.org
Background: Indacaterol is a novel, inhaled once-daily ultra-long-acting β2-agonist for the
treatment of chronic obstructive pulmonary disease (COPD). Objectives: This study …
treatment of chronic obstructive pulmonary disease (COPD). Objectives: This study …
Onset of action of indacaterol in patients with COPD: Comparison with salbutamol and salmeterol-fluticasone
B Balint, H Watz, C Amos, R Owen… - … Journal of Chronic …, 2010 - dovepress.com
Background: Indacaterol is a novel, inhaled once-daily ultra-long-acting ß 2-agonist for the
treatment of chronic obstructive pulmonary disease (COPD). Objectives: This study …
treatment of chronic obstructive pulmonary disease (COPD). Objectives: This study …
[PDF][PDF] Onset of action of indacaterol in patients with COPD: Comparison with salbutamol and salmeterol-fluticasone
B Balint, C Amos, B Kramer - International Journal of …, 2010 - pdfs.semanticscholar.org
Background: Indacaterol is a novel, inhaled once-daily ultra-long-acting β2-agonist for the
treatment of chronic obstructive pulmonary disease (COPD). Objectives: This study …
treatment of chronic obstructive pulmonary disease (COPD). Objectives: This study …
Onset of action of indacaterol in patients with COPD: comparison with salbutamol and salmeterol-fluticasone
B Balint, H Watz, C Amos, R Owen, M Higgins… - 2010 - pubmed.ncbi.nlm.nih.gov
Background indacaterol is a novel, inhaled once-daily ultra-long-acting β (2)-agonist for the
treatment of chronic obstructive pulmonary disease (COPD). Objectives this study compared …
treatment of chronic obstructive pulmonary disease (COPD). Objectives this study compared …
Onset of action of indacaterol in patients with COPD: Comparison with salbutamol and salmeterol-fluticasone
B Balint, H Watz, C Amos, R Owen… - … Journal of Chronic …, 2010 - dovepress.com
Background: Indacaterol is a novel, inhaled once-daily ultra-long-acting ß 2-agonist for the
treatment of chronic obstructive pulmonary disease (COPD). Objectives: This study …
treatment of chronic obstructive pulmonary disease (COPD). Objectives: This study …
[PDF][PDF] Onset of action of indacaterol in patients with COPD: Comparison with salbutamol and salmeterol-fluticasone
B Balint, C Amos, B Kramer - International Journal of Chronic Obstructive …, 2010 - Citeseer
Background: Indacaterol is a novel, inhaled once-daily ultra-long-acting β2-agonist for the
treatment of chronic obstructive pulmonary disease (COPD). Objectives: This study …
treatment of chronic obstructive pulmonary disease (COPD). Objectives: This study …